Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2021-2026

  • receipt Report ID : 157290
  • calendar_today Published On: Feb, 2021
  • file_copy Pages: 164
  • list Pharmaceuticals and Healthcare
Buy @ $3660

According to this latest study, the 2020 growth of Benign Prostatic Hyperplasia (BPH) Drugs will have significant change from previous year. By the most conservative estimates of global Benign Prostatic Hyperplasia (BPH) Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 3248.8 million in 2019. Over the next five years the Benign Prostatic Hyperplasia (BPH) Drugs market will register a 1.0% CAGR in terms of revenue, the global market size will reach US$ 3376 million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

The classification of Benign Prostatic Hyperplasia (BPH) Drugs includes Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors and Others. And the proportion of M Alpha-Blocker in 2019 is about 38%.

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.

Hospitals

Drugstores

Others

Benign Prostatic Hyperplasia (BPH) Drugs is widely used in Hospitals, Drugstores and Others. The most proportion of Benign Prostatic Hyperplasia (BPH) Drugs is used in Hospitals, and the proportion in 2019 is 48.97%.

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2016-2026

2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region

2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

2.2.1 Alpha-Blocker

2.2.2 Phosphodiesterase Type-5 Inhibitors

2.2.3 Others

2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2016-2021)

2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2016-2021)

2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

2.4.1 Hospitals

2.4.2 Drugstores

2.4.3 Others

2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2016-2021)

2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2016-2021)

2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2016-2021)

3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Company

3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company

3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2019-2021)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2021)

3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company

3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2021)

3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2021)

3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company

3.4 Global Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution

3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Benign Prostatic Hyperplasia (BPH) Drugs by Region

4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs by Region

4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region

4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region

4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth

4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth

4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth

4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth

5 Americas

5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)

5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)

5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region

6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021)

6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021)

6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country

7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)

7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)

7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country

8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021)

8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021)

8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Country

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors

10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer

11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast

11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region

11.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2021-2026)

11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Regions (2021-2026)

11.2 Americas Forecast by Countries

11.3 APAC Forecast by Region

11.4 Europe Forecast by Countries

11.5 Middle East & Africa Forecast by Countries

11.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type

11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application

12 Key Players Analysis

12.1 Eli Lilly

12.1.1 Eli Lilly Eli Lilly Company Information

12.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.1.4 Eli Lilly Main Business Overview

12.1.5 Eli Lilly Latest Developments

12.2 GlaxoSmithKline

12.2.1 GlaxoSmithKline Company Information

12.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.2.4 GlaxoSmithKline Main Business Overview

12.2.5 GlaxoSmithKline Latest Developments

12.3 Astellas Pharma

12.3.1 Astellas Pharma Company Information

12.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.3.4 Astellas Pharma Main Business Overview

12.3.5 Astellas Pharma Latest Developments

12.4 Sanofi

12.4.1 Sanofi Company Information

12.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.4.4 Sanofi Main Business Overview

12.4.5 Sanofi Latest Developments

12.5 Pfizer

12.5.1 Pfizer Company Information

12.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.5.4 Pfizer Main Business Overview

12.5.5 Pfizer Latest Developments

12.6 Abbott

12.6.1 Abbott Company Information

12.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.6.4 Abbott Main Business Overview

12.6.5 Abbott Latest Developments

12.7 Allergan

12.7.1 Allergan Company Information

12.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.7.4 Allergan Main Business Overview

12.7.5 Allergan Latest Developments

12.8 TEVA

12.8.1 TEVA Company Information

12.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.8.4 TEVA Main Business Overview

12.8.5 TEVA Latest Developments

12.9 Mylan

12.9.1 Mylan Company Information

12.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.9.4 Mylan Main Business Overview

12.9.5 Mylan Latest Developments

12.10 Novartis

12.10.1 Novartis Company Information

12.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.10.4 Novartis Main Business Overview

12.10.5 Novartis Latest Developments

12.11 Merck

12.11.1 Merck Company Information

12.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

12.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2019-2021)

12.11.4 Merck Main Business Overview

12.11.5 Merck Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region (2020-2026) & ($ Millions)

Table 2. Major Players of Alpha-Blocker

Table 3. Major Players of Phosphodiesterase Type-5 Inhibitors

Table 4. Major Players of Others

Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)

Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2016-2021) & ($ million)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)

Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2016-2021)

Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)

Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Application (2016-2021)

Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)

Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2016-2021)

Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2019-2021) & (M Units)

Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2019-2021)

Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2019-2021) ($ Millions)

Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2019-2021)

Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2019-2021)

Table 20. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area

Table 21. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered

Table 22. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) (M Units)

Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)

Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & ($ Millions)

Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)

Table 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)

Table 30. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)

Table 31. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)

Table 32. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)

Table 33. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)

Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)

Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Table 37. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)

Table 38. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)

Table 39. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & ($ Millions)

Table 40. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)

Table 41. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)

Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)

Table 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Table 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)

Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)

Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)

Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)

Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)

Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)

Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Table 53. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)

Table 54. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)

Table 55. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & ($ Millions)

Table 56. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)

Table 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2016-2021) & (M Units)

Table 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)

Table 59. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2016-2021) & (M Units)

Table 60. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2021-2026) & (M Units)

Table 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2021-2026)

Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2021-2026) & ($ Millions)

Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2021-2026)

Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2021-2026) & (M Units)

Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2021-2026)

Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2021-2026) & ($ Millions)

Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2021-2026)

Table 69. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 70. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 71. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 72. Eli Lilly Main Business

Table 73. Eli Lilly Latest Developments

Table 74. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 75. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 76. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 77. GlaxoSmithKline Main Business

Table 78. GlaxoSmithKline Latest Developments

Table 79. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 80. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 81. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 82. Astellas Pharma Main Business

Table 83. Astellas Pharma Latest Developments

Table 84. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 85. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 86. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 87. Sanofi Main Business

Table 88. Sanofi Latest Developments

Table 89. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 90. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 91. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 92. Pfizer Main Business

Table 93. Pfizer Latest Developments

Table 94. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 96. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 97. Abbott Main Business

Table 98. Abbott Latest Developments

Table 99. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 101. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 102. Allergan Main Business

Table 103. Allergan Latest Developments

Table 104. TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 106. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 107. TEVA Main Business

Table 108. TEVA Latest Developments

Table 109. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 111. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 112. Mylan Main Business

Table 113. Mylan Latest Developments

Table 114. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 116. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 117. Novartis Main Business

Table 118. Novartis Latest Developments

Table 119. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered

Table 121. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E)

Table 122. Merck Main Business

Table 123. Merck Latest Developments

List of Figures

Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs

Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2016-2026 (M Units)

Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2016-2026 ($ Millions)

Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021 & 2026) & ($ millions)

Figure 9. Product Picture of Alpha-Blocker

Figure 10. Product Picture of Phosphodiesterase Type-5 Inhibitors

Figure 11. Product Picture of Others

Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020

Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)

Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals

Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2016-2021) & (M Units)

Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores

Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2016-2021) & (M Units)

Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others

Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2016-2021) & (M Units)

Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)

Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2020

Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market by Company in 2020 ($ Million)

Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2020

Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Regions (2016-2021)

Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020

Figure 26. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)

Figure 27. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)

Figure 28. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)

Figure 29. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)

Figure 30. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)

Figure 31. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)

Figure 32. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2021 (M Units)

Figure 33. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2021 ($ Millions)

Figure 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020

Figure 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020

Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020

Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020

Figure 38. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 39. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020

Figure 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2020

Figure 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020

Figure 45. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020

Figure 46. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 47. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 48. Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 49. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 50. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 51. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020

Figure 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020

Figure 54. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020

Figure 55. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020

Figure 56. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 57. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 58. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 59. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 60. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 61. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2020

Figure 62. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2020

Figure 63. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2020

Figure 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2020

Figure 65. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 66. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 67. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 68. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 69. GCC Country Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2016-2021 ($ Millions)

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles